Nektar Therapeutics (India) Private Limited, a active foreign private limited company, was established on 16 May 2005 in Tirumalagiri, Telangana, India. Engaging in pharma contract r&d within the professional, scientific and technical sector, it holds CIN: U24239TG2005FTC046253. Registered under ROC Roc Hyderabad. it is unlisted. It has an authorized capital of ₹30.00 Cr and a paid-up capital of ₹29.39 Cr.
It upholds a compliant status. Employing 3 professional, Its leadership includes Mark Andrew Wilson (Director), Uday Chandra Yemmanuru (Director), Robert Michael Bacci (Director). Past directors included Raman Narasinham Akella, Jillian B Thomsen, Gilbert Mercier Labrucherie Jr. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at Plot No. 105/1, P&T Colony, Tirumalgherry, Tirumalagiri, Telangana, 500015.
U24239TG2005FTC046253
046253
16 May 2005
₹30.00 Cr
₹29.39 Cr
Roc Hyderabad
Unlisted
Active
Explore comprehensive insights into Nektar Therapeutics (India) Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Mark Andrew Wilson | Director | 19 Mar 2019 | Current |
| Uday Chandra Yemmanuru | Director | 25 Mar 2024 | Current |
| Robert Michael Bacci | Director | 18 Jun 2024 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Whole-Time Director | 17 Aug 2009 | Past |
| Pramod Abcsdd | Additional Director | 10 Jun 2015 | Past |
| Pramod Abcsdd | Director | 19 Mar 2019 | Past |
| Pramod Abcsdd | Director | 26 Sep 2019 | Past |
| Pramod Abcsdd | Director | 26 Sep 2019 | Past |
| Pramod Abcsdd | Director | 19 Mar 2019 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Nektar Therapeutics (India) Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 16.12% increase. The company also saw a substantial improvement in profitability, with a 528.99% increase in profit. The company's net worth observed a substantial decline by a decrease of 27.94%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Nektar Therapeutics (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
There are no open charges registered against the company as per our records.
Nektar Therapeutics (India) has a workforce of 3 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Nektar Therapeutics (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nektar Therapeutics (India)'s trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Nektar Therapeutics (India) Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was recorded as a recent event.
Robert Michael Bacci was appointed as a Director was appointed as a Director on 18 Jun 2024 & has been associated with this company since 1 year 5 months . was recorded as a recent event.
The activity Nektar Therapeutics (India) Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Hyderabad. was completed.
Uday Chandra Yemmanuru was appointed as a Director was appointed as a Director on 25 Mar 2024 & has been associated with this company since 1 year 8 months . was recorded as a recent event.
Progress on Mark Andrew Wilson was appointed as a Director was appointed as a Director on 19 Mar 2019 & has been associated with this company since 6 years 8 months . was documented.
The activity Phaneendra Modali was appointed as a Company Secretary was appointed as a Company Secretary on 16 Jul 2018 & has been associated with this company since 7 years 4 months . was completed.
The CIN of Nektar Therapeutics (India) Private Limited is U24239TG2005FTC046253.
Nektar Therapeutics (India) Private Limited is headquartered at Plot No. 105/1, P&T Colony, Tirumalgherry, Tirumalagiri, Telangana, 500015.
Nektar Therapeutics (India) Private Limited was incorporated on 16 May 2005.
The current directors of Nektar Therapeutics (India) Private Limited are
The primary industry of Nektar Therapeutics (India) Private Limited is Professional, Scientific And Technical.
Nektar Therapeutics (India) Private Limited is unlisted.
The authorized capital of Nektar Therapeutics (India) Private Limited is ₹30.00 Cr, and the paid-up capital is ₹29.39 Cr.
The compliance status of Nektar Therapeutics (India) Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX